Business Wire
19 May 2026, 20:00 UTC · 23w ago
Verdict
Headline leans bearish. We score TLSI −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
TriSalus Life Sciences Inc. (TLSI) lowered its full-year 2026 revenue guidance to $54 million-$57 million from the previous $60 million-$62 million range.
More negative than 95% of claims this week
The law firm Levi & Korsinsky is soliciting shareholders who suffered losses following the guidance cut to join a potential legal action.
Continue reading
5 related stories
More negative than 99% of ticker scores this week
Scored by the NIS engine · methodology.
More negative than 79% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The company lowered its full-year revenue guidance, leading to shareholder losses and potential legal action.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
3h ago
+17.5%
Price is moving against the score
$3.70 vs $3.15 close before publication (May 19) · not market-adjusted
TLSI chart →
